Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2002;105:2337-2340
Published online before print May 6, 2002, doi: 10.1161/01.CIR.0000018444.47798.94
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
105/20/2337    most recent
01.CIR.0000018444.47798.94v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Olson, T. M.
Right arrow Articles by Driscoll, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olson, T. M.
Right arrow Articles by Driscoll, D. J.
Related Collections
Right arrow Myocardial cardiomyopathy disease
Right arrow Genetics of cardiovascular disease

(Circulation. 2002;105:2337.)
© 2002 American Heart Association, Inc.


Brief Rapid Communications

Myosin Light Chain Mutation Causes Autosomal Recessive Cardiomyopathy With Mid-Cavitary Hypertrophy and Restrictive Physiology

Timothy M. Olson, MD; Margaret L. Karst, BA; Frank G. Whitby, PhD; David J. Driscoll, MD

From the Departments of Medicine, Division of Cardiovascular Diseases (T.M.O., M.L.K.) and Pediatric and Adolescent Medicine, Division of Cardiology (T.M.O., D.J.D.), Mayo Clinic, Rochester, Minn; and the Department of Biochemistry (F.G.W.), University of Utah, Salt Lake City.

Correspondence to Timothy M. Olson, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail olson.timothy{at}mayo.edu

Background Autosomal dominant hypertrophic cardiomyopathy (HCM) is caused by inherited defects of sarcomeric proteins. We tested the hypothesis that homozygosity for a sarcomeric protein defect can cause recessive HCM.

Methods and Results We studied a family with early-onset cardiomyopathy in 3 siblings, characterized by mid-cavitary hypertrophy and restrictive physiology. Genotyping of DNA markers spanning 8 genes for autosomal dominant HCM revealed inheritance of an identical paternal and maternal haplotype at the essential light chain of myosin locus by the affected children. Sequencing showed that these individuals were homozygous for a Glu143Lys substitution of a highly conserved amino acid that was absent in 150 controls. Family members with one Glu143Lys allele had normal echocardiograms and ECGs, even in late adulthood, whereas those with two mutant alleles developed severe cardiomyopathy in childhood. These findings, coupled with previous studies of myosin light chain structure and function in the heart, suggest a loss-of-function disease mechanism.

Conclusions Distinct mutations affecting the same sarcomeric protein can cause either dominant or recessive cardiomyopathy. Electrostatic charge reversal of a highly conserved amino acid may be benign in the heterozygous state as the result of compensatory mechanisms that preserve cardiac structure and function. By contrast, homozygous carriers of a sarcomeric protein defect may have a malignant course. Recognizing recessive inheritance in children with cardiomyopathy is essential for appropriate family counseling.


Key Words: genetics • cardiomyopathy • myosin




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
O. M. Hernandez, M. Jones, G. Guzman, and D. Szczesna-Cordary
Myosin essential light chain in health and disease
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1643 - H1654.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. W. Nugent, P. E.F. Daubeney, P. Chondros, J. B. Carlin, S. D. Colan, M. Cheung, A. M. Davis, C.W. Chow, R. G. Weintraub, and for the National Australian Childhood Cardiomyopat
Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study
Circulation, August 30, 2005; 112(9): 1332 - 1338.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Garcia-Castro, J. R. Reguero, A. Batalla, B. Diaz-Molina, P. Gonzalez, V. Alvarez, A. Cortina, G. I. Cubero, and E. Coto
Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the {beta}-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients
Clin. Chem., August 1, 2003; 49(8): 1279 - 1285.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
A. W. Nugent, P. E.F. Daubeney, P. Chondros, J. B. Carlin, M. Cheung, L. C. Wilkinson, A. M. Davis, S. G. Kahler, C.W. Chow, J. L. Wilkinson, et al.
The Epidemiology of Childhood Cardiomyopathy in Australia
N. Engl. J. Med., April 24, 2003; 348(17): 1639 - 1646.
[Abstract] [Full Text] [PDF]